× Key messages Background Findings Perspectives Expert commentary

RW experience with CGRP antogonists

Key messages

  • In clinical trials, calcitonin gene-related peptide (CGRP) antagonists reduced headache frequency and with minimal side effects.
  • In real-world clinical practice, CGRP antagonists demonstrated equivalent efficacy and were well-tolerated but patients reported more common side-effects, such as constipation, than reported in clinical trials.  
  • Further real-world data are needed on the long-term use of CGRP antagonists to provide additional insight on changes in treatment response over time and long-term side effects.